Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Stock Analysis & Ratings

KZR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.31 - $18.55
Previous Close$8.27
Average Volume (3M)1.86M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-7.9
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Kezar Life Sciences’s price range in the past 12 months?
Kezar Life Sciences lowest stock price was $4.30 and its highest was $18.55 in the past 12 months.
    What is Kezar Life Sciences’s market cap?
    Currently, no data Available
    What is Kezar Life Sciences’s price target?
    The average price target for Kezar Life Sciences is $19.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $22.00 ,the lowest forecast is $17.00. The average price target represents 124.54% Increase from the current price of $8.76.
      What do analysts say about Kezar Life Sciences?
      Kezar Life Sciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
        When is Kezar Life Sciences’s upcoming earnings report date?
        Kezar Life Sciences’s upcoming earnings report date is Aug 10, 2022 which is in 40 days.
          How were Kezar Life Sciences’s earnings last quarter?
          Kezar Life Sciences released its earnings results on May 12, 2022. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.023.
            Is Kezar Life Sciences overvalued?
            According to Wall Street analysts Kezar Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Kezar Life Sciences pay dividends?
              Kezar Life Sciences does not currently pay dividends.
              What is Kezar Life Sciences’s EPS estimate?
              Kezar Life Sciences’s EPS estimate is -$0.28.
                How many shares outstanding does Kezar Life Sciences have?
                Kezar Life Sciences has 60,415,585 shares outstanding.
                  What happened to Kezar Life Sciences’s price movement after its last earnings report?
                  Kezar Life Sciences reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 4.167%.
                    Which hedge fund is a major shareholder of Kezar Life Sciences?
                    Among the largest hedge funds holding Kezar Life Sciences’s share is Graham Capital Management, L.P.. It holds Kezar Life Sciences’s shares valued at 758K.


                      Kezar Life Sciences Stock Analysis

                      Smart Score
                      Price Target
                      ▲(124.54% Upside)
                      Strong Buy
                      The Kezar Life Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Kezar Life Sciences Inc

                      Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

                      Similar Stocks
                      Price & Change
                      Magenta Therapeutics
                      Xeris Pharmaceuticals
                      Scholar Rock Holding

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis